We use Google Analytics to see which pages are read and how the site is used, so we know what to improve. This only runs if you accept. See our privacy notice for details.

Joint Committee on Health

Royal College of Obstetricians and Gynaecologists Independent Expert Panel Review into Cervical Screening: Discussion

Contributions 141–290 of 290. This sitting's record is too long for one page, so it is split into 2 parts.

I have to go to the Chamber in a few minutes, but I would like to ask a question before I call Senator Burke. It arose out of evidence that we received last night, but it is something that has been on our minds as we have assessed this over the past 18 months. I refer to the balance of risk in relation to screening programmes. We understand that there is an inherent high rate of missing early changes of cervical cancer, pre-cancerous changes, and we understand that this is a problem with most screening programmes. As Dr. Henry said, 15 out of 20 will be picked up, but five will not. When one goes through the balancing of risk of a screening programme, there are instances where one looks at a slide and there is no evidence of pre-cancerous changes, even though there may be but they have not been picked up on the slide, there are instances where changes are not picked up but are evident and there are instances where major changes are not picked up.

As one moves through that gradiation, is there now a rebalancing of the risk? The witnesses last night felt that there are inherent deficiencies in screening, but CervicalCheck was outside those inherent risks. In other words, the programme was deficient. Is that rebalancing down to the limitations of screening, and ensuring that the programme is not adding a greater risk because it is in some way deficient? Is that being rebalanced at the moment? Is the programme now running at a rate efficient to the maximum of the limitations of screening?

When we invite healthy people in to have a service, for instance, screening, should there not be a no-fault compensation scheme for people damaged by the failures of the system? Might that encourage more people to come forward, because 20% of women are not being screened, for whatever reason. It may not be because they do not have confidence in the screening but rather because they just do not engage. If there was a no-fault compensation scheme in place, would that alleviate a lot of the anxiety that has developed over the last 18 months? Perhaps the three main witnesses this could comment on that.

Comment on this
Dr. Tony Holohan

I will address the first part of the Chairman's question. The RCOG review gives substantial insight and evidence into the answer to the question that the Chairman is asking. The limitations of screening was spoken about last night and there are many and varied reasons that explain the screening programme not identifying, failing to pick up on and, in about 30% of cases, failing to prevent cancers. The reasons for that can be very different, and the Chairman will be aware of this. They can be everything from the chain in terms of the issuing of call and recalls, and there could be errors there even before one gets to screening, the adequacy of the smear itself, the mounting on slides, and then ultimately, the cytology. We have heard a lot about the cytology all the way through to colposcopic diagnosis and so on.

It is true to say that where one sets the balance of risk and benefit ultimately determines the levels, broadly speaking, regarding false positives and false negatives. For most types of medical tests, not just screening, there is always a balance between the two. As Dr. Henry said, we can set the balance at a certain level which means we are over-diagnosing, we are over-treating, and exposing people to genuine harm, because over-treating means unnecessary drugs, unnecessary surgery, unnecessary time in hospital, exposure to infection and so on. All of those things have to be calibrated, and that constant calibration is an issue for all forms of medical test, but we have the best evidence that we have had in relation to the operation of our screening programme through what RCOG has done for us. On a dynamic basis, the programme would have to have its own quality assurance ranges into the future that continue to provide that assurance, but I will defer to colleagues who wish to supplement what I have said in relation to that.

On the specific issue of no-fault compensation, the committee will be aware that the Department is soon to receive the final report of Mr. Justice Meenan, who is giving consideration to the whole question of compensation. He was asked specifically how it might be applied in relation to vaccination. The point that the Chairman makes is a fair one. As part of the overall consideration of whatever recommendations Mr. Justice Meehan will make, it may form one of the considerations as to how that might operate, how that might facilitate the objectives of a population-based programme in the same way as it might in relation to something like immunisation.

Comment on this

Is Dr. Holohan saying that the balancing of risk is a dynamic assessment that is changing all the time, and that we should be looking at the programme and improving it as it progresses? For instance, we are going to move from cytology to HPV testing, which reduces the risk of missed cases. Is Dr. Holohan saying that there is a constant review of the balance of risk?

Comment on this
Dr. Tony Holohan

Yes. In broad terms for screening programmes, and as a point of principle, that has two dimensions to it. One is what the evidence says, in general terms, around the performance of tests, but then there is also the question of the risks and benefits that arise in a particular country or a particular setting. Ultimately, the costs and expenditures that accrue here will be difficult, so the cost and benefit of a screening programme, even if the technology is the same, can be different in different populations.

Comment on this

Professor Kitchener, do you have any comments?

Comment on this
Professor Henry Kitchener

The Chairman made reference to three things. The inherent limits of sensitivity that cytology screening has is the reason women are invited every three years. We know that - to use Dr. Henry's figure that one quarter of the abnormalities are not picked up in one screen - because the natural history of cancer of the cervix endures over a number of years, the hope is that they will be picked up in a subsequent screen. Repeated screening, and compliance with or adherence to repeated screening, is an important way of trying to raise the overall sensitivity of cervical screening. It is quite clear that HPV testing will reset the risk, because there will be an increased detection of underlying pre-cancerous lesions, and that will happen.

It is also the case that because women who are HPV negative are at such low risk, not just at that moment of time but in the short term, that screening intervals could increase. Regarding no-fault compensation, we do not have that in the UK and this is a matter for Irish policy-makers to consider.

Comment on this

Would any of the witnesses like to comment?

Comment on this
Dr. Peter McKenna

Looking towards the future, when HPV is introduced, an algorithm is already in place for frequency of testing. This is not a static document and it will be reviewed in the light of best international evidence and our experience here. Nothing is carved in stone as to how the programme will function in future. All we can do is to take the experience of what other countries are doing, modify it and then look to see how that works here. To say that it is an inflexible forever document would give the wrong impression. It will be modified with time.

Comment on this

I thank Dr. McKenna. I have to leave now and Deputy O'Reilly will take the Chair for the next half an hour anyway.

Comment on this

I thank the witnesses for their presentations and the work they have done on this issue. Some people have been involved from the start and some people came in at a later stage. I thank them for the detailed information provided to us. I will start with Professor Kitchener. His report states reviews were carried out of 1,000 women. It is not easy to do a review. It is a complex process and involves many people. Professor Kitchener has given that explanation, but in his report he has stated there were 20,000 data items. He might outline what those data items are, because I understood that around 3,500 smear results were reviewed. How is that total of 20,000 data items made up?

Professor Kitchener also referred to the comparison with the UK. The Irish results were similar to the UK. Regarding audits undertaken in the UK, what has been the experience regarding releasing information back to the patients? Is that process in place? I understand that in some European countries information from an audit it not released. It is retained because the whole idea of an audit is to ensure the system is working, first of all, and then that any glitches are addressed. Will Professor Kitchener deal with those issues?

I turn now to the issue of staffing and the challenges staff have faced over the past 18 months. I refer in particular to comments made by Dr. Nóirín Russell, who is based in Cork and Kerry, which set out clearly that staff have faced major challenges in some centres. I understand that in some centres there have been resignations and people have been difficult to replace. Has any mechanism been put in place to support staff who had to deal with this defensive work daily during the past 18 months? In fairness, all the staff have been doing their best to provide the best possible service. The public perception was different, however. If staff are facing challenges, it is important that they have the necessary support. The last time I raised this issue was when someone from the Medical Council was in here. I am referring to a situation where there is an adverse outcome regarding work done within the HSE or by medical staff and the lack of support available. Have we identified how we can support and retain staff?

Also on staffing, the number of consultants in this area is very small. The total number of consultants in obstetrics and gynaecology is about 135, and it is smaller again in this particular area. Have we set out how many people are due to retire in the next five years, how many people are in training and how many people we need to encourage to go into training in this area? What work is being done on that issue? I ask that because I see major challenges. For example, I have heard of two people who have dropped out of the area of obstetrics and gynaecology. One person was in training for nine years, but then decided to go back to do GP training. The second person had done six years of training in obstetrics and gynaecology before dropping out, again to do GP training. It is the same in this particular area. What supports are we putting in place? How can we now help retain those staff and ensure we have the necessary numbers of staff in place to deal with requirements and provide an adequate service for the patients? They are entitled to the best quality service and to do that it is necessary to have the staff. Those are my opening questions.

Comment on this
Professor Henry Kitchener

I will deal with one of Senator Colm Burke's questions and refer the other to Dr. Walker. The Senator asked about the policy of disclosure in England. That policy was developed some years ago by policy-makers who felt it was important that there was transparency in the system. That was what it was all about. It was a measure taken to try to increase public confidence in the cervical screening programme. Senator Burke is correct that in a number of countries with high standards of cervical screening that the results of slide audits are not disclosed to individual women. I have recently been in contact with the director of the world-renowned cervical screening programme in British Columbia. He informed me that the programme has not been doing that, but they are examining the resources put in place in England for that purpose. The Senator is correct about other countries with good programmes in Europe. We have this policy of disclosure and we think it is a good policy.

As for the response women have to this situation, a significant proportion when asked do not want to know the result of the slide review because they are content that they have been diagnosed. They may regret and be upset, of course, that cancer intervened, but having been treated they do not necessarily want rake over all of that again. Other women do want to know and when some find out they are prepared to accept the results in the context of the limitations of screening. Some women may also wish to use the results as a basis for pursuing litigation. The policy is there and the interaction women have with that policy of disclosure is a matter of individual preference. I will hand over to Dr. Walker now, if I may, to answer the question concerning the size of the data.

Comment on this
Dr. Patrick Walker

I have in my mind now the spread across as we were working on the letters. There were 1,038 women, but 1,659 slides. As we worked across the database, therefore, we had the CSPID to identify the case.

There is a slide number to identify the slide. There is the CervicalCheck result, classified as negative, low-grade or high-grade, and the P number, which is from one to nine. There are sometimes more than one P number. Then comes the review result, the review result P number, the final diagnosis from the cytology group, and the P number result - P 2 from the screener. Where the slide went to a first consultant, there is that consultant's opinion and a P number. Where there was a second consultant, there is another opinion and P number. Then there is consensus, if there was a consensus, and the subjective comments, if made. The date of attendance at colposcopy had to be tabulated against the date of diagnosis of cancer to identify the subgroup that needed to be seen. Then there is the comparison of the CervicalCheck result with the review result in terms whether it is concordant or discordant. Then there is the issue of whether a letter has been drawn up or not, or whether the letter has been completed or not, and other matters relating to stage. All these items did not come down in the dropped merged mail. They all had to be put up there and extracted. For each individual letter, there are approximately seven items to be drawn down, manually or otherwise. We sent the committee a copy of the draft letter. The point that was being made in the sentence was that this was a complex task.

Comment on this
Mr. Damien McCallion

Colleagues may also want to contribute on colposcopy. I acknowledge the work doctors, nurses and support staff have done in the 15 colposcopy units around the country. Undoubtedly during the crisis they would have been the front-line point of contact for women who were understandably anxious and concerned. The staff have provided extra sessions and done a huge volume of work to try to bring about some stability. They are still challenged in the service. What has been put in place is a working group involving the acute hospitals, the women and infants programme, Dr. McKenna and CervicalCheck, under Dr. Doherty. There is a team in place to examine a number of issues, one being investment. As I stated, €2 million was allocated this year to try to support the service in regard to both staffing and equipment. A second aspect involves looking at the clinical pathways in the utilisation of the service. The third aspect involves GP education and guidance on referrals to the colposcopy service. In addition, it is a matter of considering alternative pathways for certain categories of patients in terms of ambulatory gynaecology clinics. Colleagues could speak about this. Finally, there is a focus on planning over the next few years as we move to HPV. As we have mentioned, there is a higher impact over a number of years as one moves through HPV screening in colposcopy. Alongside that, there is a workforce piece examining some of the issues referred to in terms of planning, including medically and in the areas of nursing and other models that would have been developed. An impact assessment was done. Dr. McKenna might speak about that first before tackling the wider point. Each unit was visited last year to consider the issues and what the solutions might be. They vary around the country based on the nature and shape of the units. Dr. McKenna might speak to that first and then talk about support.

Comment on this
Dr. Peter McKenna

I very much welcome the Senator's observations on the staff. There are two important features to retaining staff in colposcopy. They must have the facilities to treat the patients coming to them. They have been under a lot of pressure owing to clinical referrals. One of our objectives is to take the clinical referrals out of the colposcopy clinics in order that they can focus on the patients who are best seen in them.

The Senator mentioned trainees dropping out. This has always been a concern in the specialty of obstetrics and gynaecology. It is not something that is suitable for everybody, for a variety of reasons, but, in fairness, colposcopy is not a reason for trainees not continuing in the specialty. It may be a very cogent reason for those becoming consultants not taking up that particular part of the profession.

The Department has allocated funding to make the conditions for the patients and the staff in the colposcopy units better but it would be remiss of me not to say the biggest difficulty the staff have in the colposcopy units is the fact that they felt they have been pilloried and demonised over the past 18 months. They are very sensitive about the negative information about them in the public domain. When that ceases, it will go a long way towards making recruitment into this area less difficult.

Comment on this

What backup support was provided to staff? Everyone knew they were under pressure.

Comment on this
Dr. Peter McKenna

A colleague and I visited every unit to know what backup support was appropriate. We went through their needs in terms of equipment, staffing and infrastructure. This is what we are trying to address in the current allocation.

Comment on this
Louise O'Reilly Acting Chairman Sinn Féin

Is the Senator referring to emotional support?

Comment on this

I am talking about emotional support because it is challenging.

Comment on this
Louise O'Reilly Acting Chairman Sinn Féin

There may have been a misunderstanding.

Comment on this

It covers both.

Comment on this
Louise O'Reilly Acting Chairman Sinn Féin

Dr. McKenna was describing physical supports. I suppose anything beyond the employee assistance programme is open to everybody.

Comment on this
Dr. Colm Henry

I welcome the Senator's comments on colposcopy staff. It is important to recognise the screening programmes are primarily about the women engaged in them. They will only be successful, however, if they have happy, engaged and supported staff, including not only colposcopists but also administrative staff. I visited the staff in Limerick on Monday. I pay tribute to them for their great resilience and for sticking with the programme over the past 18 months. The unit proved quite successful at holding on to staff in a period of markedly increased demand, not only in terms of the number of inquiries but also in terms of the nature of the interactions with the public. The Senator is quite right. To refer to what Dr. McKenna said, when we consider the needs of colposcopists and the sources of pressure on clinicians, the primary objective is to ascertain the supports they need to address the demand in their clinics. The past year has seen a remarkable increase in demand, not just through the screening service but also through direct referrals from GPs. With the support of Dr. McKenna and his colleagues, we have been seeking and securing funding for alternative pathways to ensure women can go to the right clinic for the first time and preserve the integrity of those clinics in respect of what their set-up is supposed to be.

Comment on this
Louise O'Reilly Acting Chairman Sinn Féin

I am not sure that addresses the question directly.

Comment on this
Mr. Damien McCallion

The supports for people on the ground were highlighted by Dr. Russell. The colposcopy units are under the management of the acute hospitals. The hospitals run the colposcopy clinics and the programme then funds and has a contract with the colposcopy clinics. I spoke to Dr. Russell myself. All the hospitals have asked us to ensure the necessary supports are in place in terms of employee assistance and so on. There may have been variation between hospitals in this regard over the past year but we are going to make sure that whatever is needed is provided. As we have all said and agreed, the service has been through a very difficult 18 months and continues to be under pressure. It is a bit like the laboratories in that we have to try to retain and stabilise the service and then deal with future demand. That is the purpose of the group I mentioned in terms of considering how to utilise the funding provided by the Department under the service plan and the changes to which Dr. McKenna referred.

Comment on this

The concern I have is that she had to go public to highlight the issue. I have not spoken to her directly about this but this indicated that she felt the level of support required for staff was not in place. I do not know what Mr. McCallion's view on that is.

Comment on this
Mr. Damien McCallion

In response to it, I have spoken to her myself. I do not want to personalise it, in fairness to her. She is just representing a general view. The hospital groups are being contacted to make sure that if what should be in place for them is not in place, it will be put in place. They ultimately have responsibility for managing the service from day to day. From a screening perspective, Dr. Doherty has secured a colposcopy adviser. There was a gap in this regard, and we have talked about it here. I am referring to someone within the programme to interface with the units on a day-to-day operational basis. We have just appointed someone in the past week after a long search to recruit someone. That will help from a screening perspective. Ultimately, the units work within the hospitals and we need to make sure the supports are available for them in the hospitals. There are practical aspects, which we have discussed, but there are also elements in terms of the personal impact on the staff of working in a service that is stretched and under pressure.

Comment on this
Dr. Peter McKenna

On the practical support we have offered, the RCOG report had to be disclosed to patients who wanted a meeting.

In the past, the units were written to and they were told to get on with it. On this occasion, we engaged with the units. We offered support and training as to how to do it and what was likely to lead to the best outcome for the patients and, indirectly, for the staff. Where the staff felt that they were unable to do it we provided a central team that would go to their unit and deliver these results. This is a quite significant difference from how the programme would have interacted with the individual colposcopy units in the past. More than 200 of these visits and meetings with the women have taken place to date, many of them with the local units, most with the central support team. The fact that we have not heard more about them - I am not saying that they are all going absolutely smoothly - says something for the effort that the HSE put into preparing for this event.

Comment on this
Mr. Damien McCallion

I do not think any of us is saying that there is not more work to be done with the colposcopy service. I mentioned the units were all visited last year. The intention in January, through the women and infants programme, is to visit the units again. This is in order to understand the issues at a practical level, because each unit does not necessarily have the same issues in relation to how it is functioning, how it is supported and so on. That repeat visit of each individual site will also help to identify issues for each unit that can be addressed either locally or with support from the centre.

Comment on this
Dr. Peter McKenna

In terms of whether the units need more support, the answer is yes. It is a question of how we can best provide that.

Comment on this

Has there been an assessment done of what we need to do over the next three to four years to plan for people who are retiring?

Comment on this
Dr. Peter McKenna

That is not something that centrally we have been engaged in. It is left to the individual hospitals and their groups to recruit people, but that has been brought to our attention and we will be engaging with the institute, which is the training body as to how best to ensure that this does not happen. The Senator is absolutely correct that this is a real risk.

Comment on this

Can I ask one final question?

Comment on this

The Senator may ask one quick question.

Comment on this

It is about the positive outcomes in cervical screening and the progress that has been made over the past ten to 15 years. I am not sure if enough information is out there in the public domain. For instance, the National Office of Clinical Audit published figures recently on the reduction in the number of people dying in hospitals due to heart attack, stroke or pneumonia. I do not know whether we have got enough information on the changes that have occurred over the past ten years in CervicalCheck. A lot of progress has been made and I am wondering if something can be done to get out the positive information because it has been very much a defensive role that the HSE and the Department have played over the past 18 months. I am wondering if something could be done to get that information out as well.

Comment on this
Dr. Colm Henry

One of the positive outcomes from the royal college review is that an independent outside body confirmed that this programme is working effectively. It is not just a question of us communicating figures such as the reduced mortality or the earlier detection of precancerous changes. It is the summary view of the royal college that the CervicalCheck programme is working effectively. That is a strong message of reassurance to our population, not just to those who are engaged in the programme now, but to women who are coming up to the starting age for the programme. They should have confidence that this programme works, and is effective, as benchmarked by an external, independent body.

Comment on this

It would be helpful if the indications in terms of numbers going back ten years ago, and the numbers now------

Comment on this

Senator, we have to wrap up there.

Comment on this

I am wondering if if that could be done as well to outline the changes that have occurred over the past ten years.

Comment on this

I call on Dr. Doherty to reply briefly as I am conscious of time.

Comment on this
Dr. Lorraine Doherty

I thank the Senator for his question. We do monitor the outcomes from the screening programme on the incidence of cervical cancer. As the Senator will know, before the programme was introduced cervical cancer was rising by a rate of around 4% a year. What we know from our most recent data is it is decreasing by approximately 5% to 5.5% year on year now. The most recent data we have on that is from 2016.

Comment on this

It is not generally out in the public domain-----

Comment on this

I apologise to the Senator, but we are up against it for time. I know that some of our guests have to leave. I call Deputy O'Connell.

Comment on this

I wish to follow on from Senator Burke's comments about the impact of screening on the population's health. Perhaps it is not Dr. Doherty's area, but my understanding is that before the start of the cervical screening programme ten years ago we had the highest rate of cervical cancer in Europe, and we had done nothing to try to impact on that. I think Dr. Walker said at the private briefing that it has gone down 7% year on year; that is what I wrote down that day. It may be 5.5% as Dr. Doherty said, but at least it is in the right direction. There was a comment passed here yesterday, and I am not sure if I misinterpreted it, asking if there was a material impact. It is very important that somebody with a medical background, who is qualified to say it, can say categorically here today that we used to have an increasing rate of 4% and now it is between 5.5% and 7% in the downward direction. The net impact of that is lives saved, but also that early intervention has had positive outcomes for the population for women who might have had their fertility or their personal lives affected.

It is not just about mortality. One of the witnesses said earlier on that it is about having the least impact on people's lives. Reference was also made earlier to the consequences of over-diagnosis, or dealing with false positives, and that one does not start zapping everybody with radiation if they have a small cellular change, that that has a net impact on the rest of their cells. If it was as easy as just assuming everybody had a certain low level we could zap everybody, but that is not the way it is done. One has to deal with the data in front of one on the slides-----

Comment on this

I apologise to the Deputy, but Dr. Holohan is indicating that he wants to respond directly to her.

Comment on this
Dr. Tony Holohan

I am entirely in agreement that there have been a range of improvements at a population level since the programme was commenced, not just in relation to mortality. A total of 50,000 high grade lesions have been picked up and so on over the period, and the incidence impact that we have heard about, just under 7% in the years from 2010 to 2015, is now beginning to feed into mortality. I want to take the opportunity to pick up on the point that Senator Burke was making. I refer to the importance of us being able to get into a situation where we can on a positive and a proactive basis communicate the full range of information. That has been a challenging space for the HSE, and for the Department, and for the professional colleges who would normally be in that space over the course of the past 12 to 18 months. It is something that proactively we need to get back into in the coming year, and that is something that we will be doing for sure.

Comment on this

It is important that that message is gotten out there in terms of how aggressive cervical cancer is, the population it affects, that it has life-changing impacts and that despite the best efforts, somehow we still have a system that is fit for purpose.

Comment on this
Dr. Tony Holohan

A number of us were around when the programme was commenced, and we did not have a programme in 2008, unlike our colleagues in England, and in the UK. I can recall the role that was played by the original CervicalCheck clinical director Dr. Gráinne Flannelly, in her engagements with the Department, and in public, in making strongly the case for the introduction of a screening programme. She talked in very clear and passionate terms about her gynaecological practice in the UK, where she had trained, and seeing young women presenting with late-stage cervical cancer, and lives being lost with young children. She was instrumental in making the case in public and political terms, for investment in the development of a new programme at a time, in 2008, when the overall expenditure on the health system was being reduced. There is no question that that played an important role in establishing a programme that has had the positive impacts we have seen over the past ten years.

Comment on this

It is worth noting as well the ethical challenges she faced at the time and the different space we were in as a country. There was a lot of resistance to funding for this area, and there was a lot of hearsay and all sorts of carry-on that was very hard to battle. I know that Senator James Reilly was instrumental in bringing the truth of the situation to the fore as well. To go back to today's job, I have been meeting all the witnesses at the Committee of Public Accounts and this committee for a while now and for 18 months with regard to this matter.

The words "blame" and "truth" have come up a lot. I would level the blame for this on the audit and, in particular, whoever it was who decided that it was a good idea to audit without considering the impact of the audit results. Something that was imprecise, with a 70% detection rate, was being audited so naturally the results would not be easy to read if someone fell into the other 30% all the time and had cancer. The main lesson that needs to be learned is that in the context of everything that is done by the Department and the HSE, the patient must be to the fore. The impact all the way down to the person whose slide is involved must be considered.

Another lesson from what happened involves the lack of leadership and governance. It was very clear to me and to other members of the committees that no one seemed to be in charge. There was a vacuum and this left space for falsehoods or for incomplete information to get out. A lie is halfway around the world before the truth is putting its boots on. That is really what happened in this case to some extent. I am grateful for the report and I believe in its independence. However, it is very difficult to explain to people that despite the questionable quality assurance that was in play when we were going over to see the labs, despite not noticing that slides were being sent to other labs in clear breach of contract, despite the guy in Salford operating without approval and despite all the things we discovered, it appears that our gross population data, as per the report, is not too different from that of the UK. I believe that but it is very difficult to communicate it to the public and to say that, despite all that has happened over the past 18 months, "Nothing to worry about girls, it has all been fine." That is a very hard message to get across to people and they do question it.

In terms of the labelling of slides, I can understand the complexities involved. I would like to clarify something which emerged yesterday and about which I am unhappy. Where there was a slide that was concordant with the result, it was categorised as concordant. Where a slide was discordant with the CervicalCheck result, it was discordant. Dr. Walker spoke about the non-homogenous group, namely, the third group of people. I agree with him, particularly in the context of trying to just force everybody into that group. On the basis of what he stated, they were not a homogenous group and they could have had no smears. I just want to clarify that where there was an assumption or a decision made that a slide was concordant, there was actually a physical slide present.

Comment on this
Dr. Patrick Walker

Absolutely, 100%.

Comment on this

There was no default position of concordance. That is something that came out of yesterday's meeting. I do not really know why, but it left me uncomfortable and last night I was wondering if the results are as I read them initially.

In terms of the labelling issues, there is continuous reference to the idea that a person would be as likely to win the Euromillions as to have this happen to her, which is just ridiculous because the sum is not right. In terms of looking at people's smears, there was no indication given to slide readers or operatives of who the slides belonged to. Is that not true? The process was totally anonymous. The slide readers knew that the person had cancer, because that was obviously the trigger, but they did not know it was my smear, Deputy Bríd Smith's smear or whatever. They did not know who it was. It is unfair for people to suggest that particular people were being looked at through a different lens. I think there is some element of that going on.

Comment on this
Professor Henry Kitchener

Yes, that needs to be refuted absolutely.

Comment on this

I just want to make sure because certain things are coming that are not being discussed fully and then assumptions are being made publicly. All of this damages the screening programme. I thought the whole point was to have an adequate screening programme. Lorraine Walsh spoke yesterday about oncofertility and lymphedema These are the side-effects of surviving a devastating illness. There appear to be inadequate services for people who are diagnosed and treated and then have to deal with the issues that come from surviving such a devastating illness. I understand that there are recruitment and financial issues. W are trying to get over this hump, as it were, but what work is being done with the Irish Cancer Society in terms of referral pathways for women who maybe at 32 or 34 years of age find themselves with this devastating diagnosis? They might not have anybody in their lives they can turn to. They might not be able to have children. What about freezing eggs or any of the advice that is out there? In terms of dealing with women who have an early diagnosis and treatment and the pathways for them, as cancer survivors, is there anything in train?

Comment on this
Dr. Colm Henry

With regard to lymphedema, I would like to acknowledge the work of Lorraine Walsh in advocating for this service. It is somewhat of an orphan speciality in that it does not lend itself readily to one particular specialty. We will be interviewing this Friday for a lymphedema lead. Working with the Department, we have secured funding to start up a service in the Mater Hospital and one of the community healthcare organisations. That service will address the needs and will be core to the needs. One of the core issues for some of the survivors of cervical cancer and indeed other types of cancer is lymphedema and the difficulty they have in accessing a single specialist who can signpost them. We are making progress on that and will be working with Lorraine and others in pushing it and with the Department in securing funding.

On the broader issue of cancer survival and the ten-year strategy of the NCP, part of that strategy focuses on post-cancer care which has been somewhat neglected in recent years with all the focus we have on consolidating care in our eight cancer centres and all the improved outcomes we see in that. As we see greater success with cancer survivorship, there needs to be greater focus on the needs of people who have survived cancer, which until now have not been as well addressed as they should have been. I acknowledge that.

Comment on this
Louise O'Reilly Acting Chairman Sinn Féin

With respect, Deputy O'Connell's question was about what is being done. There is acknowledgement that there is not a range of supports in place for - this is not a medical term - the fallout or aftermath of surviving cervical cancer in particular. There were a number of issues raised regarding the type of support and-or intervention that a woman might need. If I am understanding her correctly, that is the issue Deputy O'Connell wanted addressed. It is not so much an acknowledgement of it, which is grand, but more what plans are in place to deal specifically with the fallout.

Comment on this

There is this interview on Friday. There is somebody interviewing for a post.

Comment on this
Dr. Colm Henry

For the post of lymphedema lead. We have funding secured for lymphedema services.

Comment on this

In terms of fertility treatment or matters of that nature, is there even the genesis of a plan?

Comment on this
Dr. Peter McKenna

It is probably more than just a plan. The person who has kept me most aware of this is Professor Donal Brennan in the Mater, who has obtained funding from the Irish Cancer Society with a view to improving survivorship. The team is not medically based. It is multidisciplinary, including dietetics, physiotherapy, psychological counselling and that sort of thing. He will be looking for co-funding from the HSE in order that this pilot project can be rolled out long-term and for other units as well. It has gone beyond a plan. I would not be aware of this only for the tenacity of Professor Brennan in keeping me informed and looking for funding.

Comment on this

It is people like Donal Brennan who are interfacing with the patients who have survived and who have, perhaps, had their life plans altered. A bit like engaging with patient groups, we have to talk to the people it affects. I imagine that people in the Department and, from our perspective, in here can be very removed from the process.

One has to interface with patients in order to hear what they are saying.

Comment on this

Ms Conroy has indicated she wants to respond to Deputy O'Connell.

Comment on this
Ms Tracey Conroy

We have been talking about survival and as has been mentioned, survival rates for Irish cancer patients continue to improve. Survivorship is a key theme of the national cancer strategy that was approved by Government and launched in 2017 by the Minister for Health, Deputy Harris. The statistics show that in 2016 there were 173,000 people alive in Ireland who have had a cancer diagnosis. That is almost 4% of the population. In developing the cancer strategy, which was done in consultation with cancer patients, we were keen to ensure a focus on this area generally. In August, the Minister launched the National Cancer Survivorship Needs Assessment: Living With and Beyond Cancer in Ireland. That report establishes a baseline assessment of the services available to cancer survivors and it recommends models of care for future development and actions to develop cancer survivorship care across the full spectrum of care required. We are very focused on that. Under the auspices of the cancer strategy, a cancer patient advisory committee has been established. That builds on the work of the cancer forum that developed the strategy. We have 15 members selected to sit on that committee and it meets actively to work on those issues, including survivorship. The Department is strongly focused on the ongoing need for funding of these services, particularly survivorship services across the spectrum of care. There is a lot of work still to be done on that.

Comment on this
Dr. Tony Holohan

While I do not want to take further from Deputy O'Connell's time, I should point out that the Minister will shortly bring proposals to Cabinet for consideration on assisted human reproduction and on the development of a model of care. We have worked with the HSE in the development of same. This is for the full range of assisted human reproduction services to sit alongside the drafting of the legislation. Members will be aware of this as they completed pre-legislative scrutiny of that legislation in July. We will be considering the committee's recommendations as part of the drafting. We hope to have the Bill drafted by the end of quarter 1 and to be in a position to move on the development of the services.

Comment on this

I am fully aware of that through my work on this committee. People often get a quick and unexpected cancer diagnosis. They often then fall foul of interventions such as having their eggs frozen in short order and money is taken from them in a frenzied situation where there is a lack of information. If cancer patients are being supported in this way, it has be structured with clear evidence coming from qualified clinicians as opposed to people who want to make a few euro out of people at their lowest moment.

On the laboratories, we have five laboratories now which are subject to quality assurance visits. It is, therefore, a different picture from what we saw a year or 18 months ago. Is it a completely different picture with regard to custody over slides and governance? I imagine it is far more robust now and it will be much easier to audit if we ever have to audit again. We are no longer trying to find laboratories in Salford, Honolulu or wherever. We know where the laboratories are, that the slides will stay in them and be available to be looked at, and that the quality assurance is up to scratch. Is that fair to say?

Comment on this
Dr. Lorraine Doherty

That is fair to say. We know where all the laboratories are. They are all on the eastern seaboard of the United States. They are all linked in to a common system in Quest Diagnostics. As I alluded to earlier, they have good quality assurance measures in place. Most importantly, we have a close working relationship with them now, including regular meetings, and they are working closely with us every week.

Comment on this

Lorraine Walsh told the committee yesterday that she wants to stop looking back and instead look forward and she wants us to work together. This has been a testing time for many of us on the committee. Our job is to interrogate what went wrong. I know it has been difficult for many of the witnesses and many staff working in the system. I ask them, however, to understand where we are coming from. It is very difficult to explain to the public that the test being provided to women was only 70% accurate. Some women do not think about having a smear test but most do not look forward to it. It is something they do because they have bought into the system. It was very difficult to meet women or families who had lost people. In the information vacuum we had in the immediate aftermath of this crisis, the medical people at the top of the Department - I have the height of respect for Dr. Holohan and Dr. McKenna - should have taken hold of the reins. There are lessons for all of us in this. I am not saying I am blameless either but there should have been better leadership at the top, especially when so much was at stake. We had the roll-out of a large population-based screening programme involving an invasive test for a cancer that is personal to people and has affected many families. It was such a basket case of a situation 18 months ago. I genuinely believe the position has improved, although we could not possibly have gone any further backwards, and we will learn from this experience.

Stephen Teap spoke at our meeting yesterday about the lack of organisation and leadership. The medical person, Dr. Gráinne Flannelly, who has arguably saved more lives than anyone in this room, was the first person to get the chop. Lessons have to be applied from what we have learned today. If I have the privilege of being a Member of these Houses in the next term, I will be disappointed if we ever again come across such a lack of organisation or top-down accountability in the HSE or the Department. It is regrettable for population health that we have ended up where we are today. It is testament to the work of all the witnesses, the laboratories and the patient advocates that we can, as a result of the report from RCOG, say that despite all that has happened, the screening programme has not been pointless or a waste of time and money because women have lived who would ordinarily have died and women have had better outcomes than they would have had if there had not been a screening programme. I thank all the witnesses for their time.

Comment on this

I thank the Deputy. There was no question there so unless the witnesses want-----

Comment on this

There does not have to a question.

Comment on this

I am alerting our witnesses to the fact that they do not have to respond unless they wish to.

Comment on this
Dr. Tony Holohan

I feel tempted to respond to the question on whether we could have done a better job in the leadership of all of this. That is probably true. All I will say, and this is a personal reflection, is that it was a difficult time for everybody. That is not any form of excuse. In the public engagements in the early days of this, there was a concerted effort to do exactly what Deputy O'Connell is reasonably suggesting, namely, to establish and provide clear communications. Good work was done in that regard between the colleges, the HSE and others. It got to a point where communicating in public and doing our jobs in public in the normal way became almost impossible. I am not reflecting on that in terms of us doing our jobs alone, but it impeded our ability to be able to provide the assurance to people who were using the services. That is where the regret is. However, we are a long way down the road, as the Deputy has said, in learning the lessons that come from this. The Minister and many others have made clear publicly that mistakes were made and there are lessons to be learned. Everybody across the board is committed to ensuring the lessons that have been set out for us in the Dr. Scally report and elsewhere will be fully implemented.

Comment on this

It would be remiss of us at this point not to acknowledge that, notwithstanding the difficulties faced by people in this room and in the employment of the service, extreme difficulties were faced by the women affected and their families. We should also acknowledge that. Our last speaker is Deputy Bríd Smith. I am conscious of time because two of the witnesses have to leave to catch a flight.

Comment on this

I thank the witnesses for their contributions. As they will know, the committee heard from Stephen Teap and Lorraine Walsh yesterday. I was particularly struck by Ms Walsh's lack of confidence in the RCOG report. We have had a lot of discussion about the need for confidence in the screening system.

I for one am an advocate of screening. I have taken part in it all my life and I would never undermine the need for it and the recognition that it saves lives. To ask questions is not a mortal sin and, in some ways, the statements that the questioning by others is leading to a lack of confidence are really over-exaggerated. I understand that RCOG has stated that unfounded criticism of its evidence-based report could undermine trust in its findings. The witnesses should probably tell us where that unfounded criticism is coming from. The one critic that I heard here yesterday was Ms Lorraine Walsh. Some people in this room think it is no big deal that in the two most high-profile cases, hers and Vicky Phelan's, the slides were confused-----

Comment on this

Who is Deputy Smith referring to?

Comment on this

I am referring to Deputy O'Connell.

Comment on this

If a charge is going to be made-----

Comment on this

Nobody is making a charge. Hold on for one moment.

Comment on this

Can we de-anonymise the charges please?

Comment on this

We have already discussed this issue, Deputy Smith. The Deputy knows that it is not appropriate for her to make charges against any person who is here. If the Deputy has a charge to make, she should not make it anonymously.

Comment on this

I am not making it anonymously. I am saying that Deputy O'Connell has said that it is not like a lottery that the two slides got mixed up. To say that it is an exaggeration.

Comment on this

That is what Deputy O'Connell said, not what Deputy Smith had inferred.

Comment on this

I will allow Deputy O'Connell to respond to that.

Comment on this

We are short on time. To intimate that-----

Comment on this

I am not short on time.

Comment on this

I am sorry, our witnesses are short on time. Could Deputy O'Connell respond and keep it exceptionally brief? I do not think we do anyone any service by continuing this.

Comment on this

I do not think I will dignify it with a response.

Comment on this

Fair enough. I ask Deputy Smith to resume.

Comment on this

I believe that is an extraordinary coincidence that they were mixed up. So does Lorraine Walsh. She has lost confidence in the RCOG report. She also said that she felt that women were not being listened to and she felt bullied by the Department.

Comment on this

We had a session beforehand and agreed that, given the nature of the evidence that was given to us yesterday, we are not going to go down the road of directly addressing the comments that were made because it may identify a person. I have fallen foul of this myself because I missed the earlier session but was briefed by the Chair before I sat in here. As the Deputy knows, it is read out at the beginning of every session that we do not do that at these committees. I ask the Deputy to refrain from mentioning those.

Comment on this

Okay. I will park that. Deputy O'Connell also referred to her colleague, Senator Reilly, who advocated for the introduction of a national screening programme. At the time, he stated:

I understand several laboratories are now accredited, including Beaumont/Rotunda, RCSI, St. James's Hospital through its connection with Antrim and Altnagelvin Hospital, which has looked after the needs of Donegal, Sligo and Leitrim. St. Luke's is also mid-way through the process.

Having pointed out all that, he said: "This call for action obviously fell on deaf ears". He continues to say that instead of addressing this issue and ensuring that our laboratories would be in a position to tender for and successfully provide cytology, there was a rushed and ill-considered decision that has serious consequences for our health service and for the health of our women and further begs the question as to why we sought out partners in the USA. At the time, the unions, professionals, academics and many politicians advocated against the outsourcing of our health service to the USA. Why do all the bodies here think this is not an issue, when they have settlements for several millions in several high-profile cases from laboratories in the USA? Are the bodies here happy with the way those laboratories were run when we knew they were not ISO-accredited, they were processing 100 slides per day compared with an average of 30 to 60 in Irish laboratories, that the standards were lower and all the evidence from Dr. Scally? Why is there not something to look at? The NHS has a document in which it advises on the guidance of applying duty of candour and disclosure for audit results. It states "sometimes it can be hard for screening services to know how to distinguish between a false negative/false positive that has occurred because of the limitations of screening and a false negative/false positive that has occurred because something has gone wrong". I note "something has gone wrong" is written in italics. Something went wrong in the cases of the women with whom the laboratories settled for millions. More cases are coming up. Cases have fallen outside the audit and outside the RCOG report that are now coming to light too. That will go to court and cannot go through this non-adversarial process. Nobody has actually looked at what went wrong. This is a problem and it is very disappointing that RCOG was not able to look at it either. Something has to have gone wrong when one hears evidence that states that Dr. Scally told us that he could not look at the particulars in Lorraine Walsh's case because the laboratory told him it did not have the records.

An answer to a parliamentary question about the missing slides stated that more than 1,700 slides were transferred for the RCOG report. The HSE reported that during the process, a total of 35 slides of women or their next of kin who had consented were not located by the laboratories at the closing date for the slides to be transferred on 7 June. Does that inspire confidence? I am not trying to undermine the process, the screening or the need for it, but does that inspire confidence in laboratories that tell Dr. Scally that they cannot investigate the particulars of very serious and high-profile cases because the evidence is missing and that somehow cannot find 35 slides that should have been part of the RCOG report? As it happens, many of those 35 slides had serious misreadings. My final question to RCOG is, if it had those slides and they had serious misreadings, would that change the outcome of its judgment that what happened here in Ireland is broadly in line with the audit of what happened in Britain? I do not believe it reflects it. I think it would change it and the headline here is that we are broadly in line, in our audit, with what happened under the NHS.

Comment on this
Professor Henry Kitchener

As to whether the fact that 35 slides were missing would have made a material difference to our-----

Comment on this
Professor Henry Kitchener

I do not believe that would have made a material difference. I do not think that those slides as a sample would be qualitatively different from the very large sample that we reviewed. In other words, the ratio of concordant and discordant findings would not have been any different. The Deputy suggested that given all of the cancers that have developed following involvement in the CervicalCheck programme, that is surely a sign that all is not well. I refer back to the fact that, as has been said on multiple occasions today, cervical screening will simply not prevent every case. Each and every one of these cases is of major consequence to the lives of women. In this cohort, a very large proportion of women were caught at a very early stage which, as Deputy O'Connell has indicated, means that women can avoid some of the more unpleasant consequences of, for example, radical treatment. Despite all of that, that does not mean that the programme is not working. Those two matters are not-----

Comment on this

I understand that. Why does the report state that in 159 of these cases, the difference was judged by RCOG to have been a difference that could have represented an opportunity to prevent cancer or to provide a diagnosis at an earlier stage?

Comment on this
Professor Henry Kitchener

We said that because we identified abnormal cells that had not been originally detected either because high-grade cells were found as opposed to low-grade findings in the slide, or the original slide was negative and we found abnormal cells.

We were able to come to the determination that depending on the length of delay that was engendered by the original result, as opposed to what would have happened with the review result, in a specific number of cases it had exerted an impact and that had the RCOG result been available at the time of the original result, a different course of action would probably have taken place, which might have prevented the disease or led to its diagnosis at an earlier stage.

Comment on this

Does Professor Kitchener agree that the fact the slides were missing from the overall results given could have changed that percentage level, in line with the NHS?

Comment on this
Professor Henry Kitchener

I do not believe that would be the case because=====

Comment on this

Could it have been the case if many of them were found to be discordant?

Comment on this
Professor Henry Kitchener

My initial comment was that there is no reason to believe that the missing slides would be materially different in nature to the large number of slides that were found. I would expect to see similar proportions with discordant results and similar proportions with concordant results. I do not think it would have affected the result. We would have liked every single slide to have been available for review but the fact that some were not would not, I think, have altered our conclusions.

Comment on this

Professor Kitchener's position is that he does not "think" it would have altered the result but he cannot be sure.

Comment on this
Professor Henry Kitchener

I am certain that those missing slides would not have materially affected our conclusions.

Comment on this

Professor Kitchener is certain of that-----

Comment on this
Professor Henry Kitchener

I am.

Comment on this

-----despite that many of them could be seriously discordant.

Comment on this
Professor Henry Kitchener

What I am certain about is that it would not have altered the conclusions of our aggregate report. It may have altered the detailed content of individual letters because it may have allowed us to include that slide in our determination. Would Dr. Walker like to add anything further?

Comment on this
Dr. Patrick Walker

I think Professor Kitchener has summarised it very well.

Comment on this

Does everybody present today - the representatives of the HSE, the Department and RCOG - believe that there have been seriously high settlements in the courts for women who have been failed by these tests, particularly on the part of the US laboratories?

Comment on this
Mr. Damien McCallion

In terms of court settlements, they are obviously outside of our domain. As discussed earlier, we know there is a false negative rate in terms of cervical screening. The issue of negligence and so on is a matter for the courts. We do not get involved in that area. Earlier Dr. Doherty described well the focus there is now on the quality assurance around both laboratories, the Coombe and Quest. We visit both laboratories and we monitor both and we work closely, operationally, with them. There is increased operational management, as well as quality assurance in the laboratories to try to strengthen them going forward. This will continue through to the HPV primary screening.

Comment on this

Would any of the witnesses like to comment on my assertion that nobody is looking into "the something" that went wrong, which is in the guidelines issued by the NHS, which are regularly quoted. Has anybody looked into the "something" that went wrong? I accept the points regarding the limitations of screening, false negatives and false positives but when "something" goes wrong, should not there be an investigation?

Comment on this
Mr. Damien McCallion

Quality assurance will try to identify that in regard to the overall programme in terms of laboratories, not only at laboratory level but at individual screener level in terms of improvement, learning and education. That is part of any good screening programme. The original audit was constructed to examined education and learning opportunities also. In regard to the expert group that we have set up around interval cancers, that is one of the aspects on which it will come back with recommendations. That will be incorporated into the recommendations for implementation going forward. There are a series of steps that are examining quality at a much lower level, including, as I said, at individual screener laboratory in the Coombe and in Quest, which are the two current providers.

Comment on this

I understand Dr. Doherty recently visited the US laboratories. As of now, how many slides per day are reviewed by each cytologist?

Comment on this
Dr. Lorraine Doherty

Today?

Comment on this

Currently, as opposed to in the past.

Comment on this
Dr. Lorraine Doherty

The workload is concentrated into five laboratories. The volume of work that comes through each laboratory varies on a daily basis and so I cannot tell the Deputy how many exactly are being reviewed today.

Comment on this

Can Dr. Doherty give me the average number reviewed per day?

Comment on this
Dr. Lorraine Doherty

It is less than 80 per day. We have a list of all of the cytoscreeners involved in the programme. We know exactly what days they were working and we know who is dedicated to Irish work. For example, when we visited the laboratories, we noted that they have established dedicated teams who only screen Irish work and have specific requirements to meet in terms of that work. In the Quest laboratories, there is now great attention to the quality of service it is delivering for the Irish programme.

Comment on this

Is Dr. Doherty happy that they are reviewing the average rather than-----

Comment on this

I apologise for interrupting Deputy Bríd Smith, but I am conscious that Professor Kitchener and Dr. Walker need to leave now to catch a flight back to the UK. I thank them for attending the committee two weeks ago to brief us the report and for being here today to give evidence to the committee, which was very valuable.

Comment on this
Dr. Patrick Walker

We mean no discourtesy to Deputy Smith. I am sorry not to be able to remain until the end of the meeting.

Comment on this

If there are no further questions we will conclude at this point.

Comment on this

May I put a question to Dr. Holohan, please?

Comment on this

We were told yesterday that when one of the women involved in the high profile cases asked Dr. Scally what had happened in the CPL laboratory with regard to her slide, his response was that the laboratory told him that the records had been destroyed and as such, it was not possible to tell her exactly what had happened in her case. Does Dr. Holohan find that shocking? Does it inspire confidence in the laboratories?

Comment on this
Dr. Tony Holohan

I am not aware of the conversation to which the Deputy refers or what exchange of information took place.

Comment on this

I am told I cannot identify people but I am speaking about the woman who appeared before the committee yesterday.

Comment on this
Dr. Tony Holohan

In regard to the laboratories and the findings, I am familiar with Dr. Scally's views as set out in his report. I am not familiar with the conversation to which the Deputy refers.

Comment on this

Does Dr. Scally say in his report that the laboratories refused to, or could not, co-operate?

Comment on this
Dr. Tony Holohan

I cannot recall a part of the report in which he said exactly that. I will have check the report. Is there something specific the Deputy can direct me to?

Comment on this

No. I do not recall him having said that in the report-----

Comment on this
Dr. Tony Holohan

I do not either.

Comment on this

-----but I heard the woman say that he told her that the laboratory could not provide details of her history.

Comment on this
Dr. Tony Holohan

I am not in a position to make any observation on that matter.

Comment on this

Would Dr. Holohan be shocked if that was the case and it was mentioned in Dr. Scally's report?

Comment on this
Dr. Tony Holohan

I will not be drawn one way or the other on what my reaction would be to a conversation I know nothing about.

Comment on this

I was surprised to hear that was the case, in particular as it was not mentioned in Dr. Scally's report.

Comment on this

If the Deputy wishes to do so, she can provide the details of the case and we can forward them to the Department.

Comment on this

It is on record in regard to the committee's meeting yesterday.

Comment on this

We can follow up on a specific case, if the Deputy has details.

Comment on this

The RCOG witnesses have left. There was an assumption that all of the missing slides were discordant but Professor Kitchener stated in one of his responses that it is not known if they were discordant because they are missing. As he is not here to clarify that point, perhaps Dr. Henry would do so. Am I correct that the point he was making is that inclusion of the missing slides would not have had a material effect on the overall aggregate data. I would not like to hear that on the news this evening as fact.

Comment on this

My understanding is that they are not missing, they just were not submitted to RCOG in time for its review.

Comment on this
Dr. Colm Henry

My understanding of what Professor Kitchener said is that he had no reason to believe there would be any difference in the relative proportion of concordant and discordant slides that were missing and, as such, he was certain they would not have made any substantial difference to the aggregate report.

Comment on this

I thank Dr. Henry.

Comment on this
Dr. Tony Holohan

Professor Kitchener made it clear in earlier evidence that it was not a homogeneous group.

Some were missing and some were not submitted. There is a series of different reasons in each of the cases to account for-----

Comment on this

He clarified that the default position was not concordant.

Comment on this
Dr. Tony Holohan

He clarified that, yes.

Comment on this
Bernard Durkan Deputy Bernard J. Durkan Fine Gael

Confidence is an important issue that we have to look at from two perspectives. The confidence of patients, victims and their families has been seriously dented, which is absolutely understandable. If it had not been affected, it would not be a normal reaction at all. We have to take on board what we have been told after thorough investigation, particularly in view of all the medical expertise that is available to us. Do the HSE and Department of Health have confidence in the RCOG report?

Comment on this
Dr. Tony Holohan

Yes.

Comment on this
Dr. Peter McKenna

I do not think it is illogical or incompatible to be able to express the deepest possible sympathy to the patients who have concerns about the report but at the same time to also be able to express very deep confidence in the report of the RCOG that has been submitted. In the future, the RCOG report will be regarded as a milestone. It will be referenced for many years to come. It is direct and very helpful. I hope it will be part of the epitaph of what has been a very cathartic situation for the screening service.

Comment on this

I thank Dr. McKenna. On behalf of the committee, I thank our guests, Dr. Glynn, Dr. Holohan, Ms Conroy and Ms O'Callaghan from the Department of Health and Mr. McCallion, Dr. Henry, Ms Fitzgerald, Dr. Doherty and, last but not least, Dr. McKenna from the HSE. I wish everyone a happy Christmas and a healthy new year.

Comment on this